|
42 Companies |
|
63 Products |
|
63 Products |
|
53 Mechanisms of Action |
|
1 Trial |
|
232 News |
|
| 12345» |
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 15, 2019
P2, N=11, Completed, Sponsor: Rondeep Brar
Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Phase classification, Enrollment change, Trial termination: Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia (clinicaltrials.gov) - Aug 23, 2018
P1, N=7, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017 Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply
- | NN1213 / Novo Nordisk
Trial completion: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay (clinicaltrials.gov) - Jul 11, 2018
P=N/A, N=16, Completed, Sponsor: University of Washington
Phase classification: P=N/A --> P1 | N=25 --> 7 | Active, not recruiting --> Terminated; Expiration of study supply Active, not recruiting --> Completed
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Jun 12, 2018
P2, N=121, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=61 --> 121
- | Enrollment change, Trial termination: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2018
P1, N=17, Terminated, Sponsor: Stanford University
Active, not recruiting --> Completed | N=61 --> 121 N=30 --> 17 | Recruiting --> Terminated; Accrual factor
- | Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 31, 2018
P1, N=10, Terminated, Sponsor: University of Southern California
N=30 --> 17 | Recruiting --> Terminated; Accrual factor N=35 --> 10 | Trial completion date: Mar 2019 --> Aug 2017 | Recruiting --> Terminated | Trial primary completion date: Mar 2018 --> Jul 2017; Insufficient Accrual
- | mitoxantrone / Generic mfg., gemcitabine / Generic mfg.
Trial termination: Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 22, 2018
P2, N=24, Terminated, Sponsor: The Cleveland Clinic
Completed --> Terminated; If </= 5 of the initial 18 patients had a CR, the study would be stopped. Only 5 patients (21%) of 24 enrolled patients had a CR so the study was terminated.
- | Trial primary completion date: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 11, 2018
P1, N=30, Recruiting, Sponsor: Stanford University
Only 5 patients (21%) of 24 enrolled patients had a CR so the study was terminated. Trial primary completion date: Dec 2017 --> Dec 2018
- | Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment change, Trial termination, Trial primary completion date: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 5, 2017
P1, N=1, Terminated, Sponsor: Bruno C. Medeiros
Trial primary completion date: Dec 2017 --> Dec 2018 N=19 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2015; logistics
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Enrollment open, Trial primary completion date: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 14, 2017
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
N=19 --> 1 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2015; logistics Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Jul 2019
- | Enrollment open: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 14, 2017
P1, N=30, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Jul 2019 Active, not recruiting --> Recruiting
- | Zolinza (vorinostat) / Merck (MSD), Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Combination therapy: Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2017
P2, N=31, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Recruiting N=107 --> 31
- | Trial completion: Studying Tissue Samples to Learn More About Drug Resistance in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2017
P=N/A, N=40, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
N=107 --> 31 Not yet recruiting --> Completed
- | Biomarker, Trial completion, Adverse events: Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=257, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed Not yet recruiting --> Completed
- | Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=220, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed Not yet recruiting --> Completed | Initiation date: Aug 2011 --> Jan 2012 | Trial primary completion date: Sep 2011 --> Feb 2012
- | Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=30, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Completed | Initiation date: Aug 2011 --> Jan 2012 | Trial primary completion date: Sep 2011 --> Feb 2012 Not yet recruiting --> Completed | Initiation date: Sep 2010 --> May 2009 | Trial primary completion date: Oct 2010 --> Jun 2009
- | cytarabine / Generic mfg.
Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy (clinicaltrials.gov) - May 17, 2017
P=N/A, N=200, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Not yet recruiting --> Completed | Initiation date: Sep 2010 --> May 2009 | Trial primary completion date: Oct 2010 --> Jun 2009 Not yet recruiting --> Completed | Initiation date: Oct 2009 --> Jul 2010 | Trial primary completion date: Nov 2009 --> Aug 2010
- | lithium carbonate ER / Generic mfg.
Trial completion, Enrollment change: Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2017
P1, N=12, Completed, Sponsor: Paolo Caimi, MD
Not yet recruiting --> Completed | Initiation date: Oct 2009 --> Jul 2010 | Trial primary completion date: Nov 2009 --> Aug 2010 Active, not recruiting --> Completed | N=24 --> 12
- | Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 20, 2017
P1, N=35, Recruiting, Sponsor: University of Southern California
Active, not recruiting --> Completed | N=24 --> 12 Trial primary completion date: Mar 2016 --> Mar 2018
- | cytarabine / Generic mfg., clofarabine / Generic mfg.
Trial completion, Trial primary completion date: Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 19, 2017
P1, N=53, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Mar 2016 --> Mar 2018 Active, not recruiting --> Completed | Trial primary completion date: Nov 2008 --> Jan 2015
- | Trial primary completion date: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 15, 2017
P1, N=30, Active, not recruiting, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Nov 2008 --> Jan 2015 Trial primary completion date: Feb 2017 --> Dec 2017
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Feb 23, 2017
P2, N=61, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Feb 2017 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2013
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 30, 2017
P1, N=19, Active, not recruiting, Sponsor: Bruno C. Medeiros
Trial primary completion date: Dec 2016 --> Dec 2013 Trial primary completion date: Dec 2016 --> Dec 2019
- arsenic trioxide / Generic mfg.
Enrollment change, Trial withdrawal: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 5, 2016
P2, N=0, Withdrawn, Sponsor: Stanford University
Trial primary completion date: Dec 2016 --> Dec 2019 N=16 --> 0 | Not yet recruiting --> Withdrawn
- | Mylotarg (gemtuzumab ozogamicin) / Pfizer
Trial completion: RAEB-t: Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Sep 20, 2016
P3, N=600, Completed, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
N=16 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- metformin / Generic mfg., cytarabine / Generic mfg.
Trial primary completion date: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) - Sep 2, 2016
P1, N=2, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Jul 2018
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion: Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission (clinicaltrials.gov) - Jun 26, 2016
P2, N=51, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jul 2016 --> Jul 2018 Active, not recruiting --> Completed
- | Biomarker, Trial completion, Trial primary completion date, IO biomarker: Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Trial completion, Trial primary completion date: Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 (clinicaltrials.gov) - May 19, 2016
P=N/A, N=1000, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=234, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=250, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Trial completion, Trial primary completion date: Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=98, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=97, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- | Trial completion, Trial initiation date, Trial primary completion date: Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016
- Enrollment closed: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2016
P1, N=30, Active, not recruiting, Sponsor: Stanford University
Recruiting --> Completed | Initiation date: Oct 2009 --> May 2009 | Trial primary completion date: Jan 2100 --> May 2016 Suspended --> Active, not recruiting
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 27, 2016
P1, N=19, Active, not recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Active, not recruiting Suspended --> Active, not recruiting
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Enrollment closed: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 27, 2016
P2, N=33, Active, not recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Active, not recruiting Suspended --> Active, not recruiting
- cytarabine / Generic mfg.
Biomarker, Trial completion: S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=310, Completed, Sponsor: Southwest Oncology Group
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Trial primary completion date: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Mar 10, 2016
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Jul 2017
- metformin / Generic mfg., cytarabine / Generic mfg.
Enrollment closed, Enrollment change: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) - Feb 24, 2016
P1, N=2, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Feb 2016 --> Jul 2017 Recruiting --> Active, not recruiting | N=28 --> 2
- Ninlaro (ixazomib) / Takeda
Enrollment change, Trial termination, Trial primary completion date: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 26, 2016
P2, N=4, Terminated, Sponsor: Bruno C. Medeiros
Recruiting --> Active, not recruiting | N=28 --> 2 N=16 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Nov 2015; Regulatory
- Synribo (omacetaxine mepesuccinate) / Teva
Trial termination: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Jan 15, 2016
P2, N=2, Terminated, Sponsor: Roswell Park Cancer Institute
N=16 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Nov 2015; Regulatory Active, not recruiting --> Terminated; Major revisions needed in study
- Trial completion, Enrollment change, Trial primary completion date: Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission (clinicaltrials.gov) - Dec 31, 2015
P2, N=263, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Terminated; Major revisions needed in study Recruiting --> Completed | N=200 --> 263 | Trial primary completion date: Dec 2013 --> Jul 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Dec 21, 2015
P2, N=14, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed | N=200 --> 263 | Trial primary completion date: Dec 2013 --> Jul 2015 Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015
- cytarabine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2015
P2, N=134, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | N=47 --> 14 | Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Completed | N=195 --> 134 | Trial primary completion date: Sep 2016 --> Dec 2015
- Synribo (omacetaxine mepesuccinate) / Teva
Enrollment closed, Enrollment change, Trial primary completion date: Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 25, 2015
P2, N=2, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | N=195 --> 134 | Trial primary completion date: Sep 2016 --> Dec 2015 Recruiting --> Active, not recruiting | N=60 --> 2 | Trial primary completion date: Nov 2018 --> Nov 2015
- Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 16, 2015
P1, N=19, Recruiting, Sponsor: Bruno C. Medeiros
Recruiting --> Active, not recruiting | N=60 --> 2 | Trial primary completion date: Nov 2018 --> Nov 2015 Suspended --> Recruiting
- Ninlaro (ixazomib) / Takeda
Enrollment open: Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 16, 2015
P2, N=16, Recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Recruiting Suspended --> Recruiting
- Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
Enrollment open: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 16, 2015
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
Suspended --> Recruiting Suspended --> Recruiting
- Enrollment open: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Nov 15, 2015
P1, N=30, Recruiting, Sponsor: Stanford University
Suspended --> Recruiting Suspended --> Recruiting